ZNTL
Zentalis Pharmaceuticals, Inc.Company with tickers: ZNTL
CIK
1725160
CUSIP
98943L107
Shares Outstanding
71,186,348
13F Activity (30d)
96 filings
94 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $37,855,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Research & Development | $28,716,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Operating Income | $-37,855,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| Net Income | $-35,352,000 | USD | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Basic) | $-0.50 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |
| EPS (Diluted) | $-0.50 | USD/shares | 2026-03-31 | 10-Q | 2026-05-12 |